Interview with Viktor Shafranskyi, General Manager, IPSEN Ukraine
Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian…
Address: 36 Pushkinskaya street, O1004, Kiev,Ukraine
Tel: 380445026529
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2010. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2010, R&D expenditure totaled more than €220 million, above 20% of Group sales. The Group has total worldwide staff of close to 4,500 employees.
Ipsen started its activities in Ukraine 20 years ago, with the promotion of a group of legacy products, the majority of which were dedicated to the treatment of gastrointestinal diseases. A couple of years later, Ipsen introduced its innovative franchise, whose three main therapeutic areas are in oncology, endocrinology, and for the treatment of neuro-muscular disorders. For the moment, the company’s strategic focus is to expand its innovative franchise and to push these medicines forward into the market.
Over the past seven years, the range of strategic products in Ipsen’s Ukraine portfolio has more than doubled. At the beginning of 2004, about 30% of sales came from the innovative franchise, whereas by the end of this year, around 60% of sales is expected to be generated by innovative medicines.
In both its targeted therapeutic areas and primary care, Ipsen has a diversified portfolio of leading drugs.
The Group’s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology, hematology), which are its primary areas of development. The Group also markets products in other therapeutic areas in which it boasts longstanding expertise (gastroenterology, cardiovascular and cognitive disorders). To a large extent, these are composed of primary care.
Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian…
Eugene Zaika, general director Ukraine and CIS of Pharma Start, a company acquired in October 2015 by Swiss-headquartered Acino Group and one of the leading players in Ukraine, provides insights…
Ludmila Bezpalko, CEO of Borshchahivskiy Chemical Pharmaceutical Plant (BCPP), a top 10 domestic pharmaceutical company in Ukraine, documents the development strategy she has been following over the past two decades…
Alexander Boiko, general manager of Novo Nordisk Ukraine, provides insights into the recent progress and remaining room for improvement in Ukraine’s health capacity when it comes to preventing, diagnosing, and…
Vladimir Tkachenko, general manager of AMAXA PHARMA, a UK-headquartered pharmaceutical company focused on life-threatening therapeutic areas such as oncology and neonatology in the CIS countries, provides insights into AMAXA’s market…
Mykola Gumenyuk, CEO of Yuria-Pharm, documents the strategy that has been driving the impressive growth of this ambitious company, how Yuria-Pharm has evolved into the leading manufacturer of solutions for…
Andy Hunder, president, and Maxim Proskurov, policy officer for healthcare issues, at the American Chamber of Commerce (AmCham Ukraine), provide insights into the Chamber’s main actions and strategic priorities as…
Rajeev Gupta, co-founder and MD of Kusum Group, the largest Indian company in Ukraine, providing domestically produced generic treatments to the Ukrainian market, describes the challenges of the procurement process…
Tetyana Dumenko, director of the State Expert Center (SEC) of the Ministry of Health of Ukraine, the regulatory agency responsible for product registration, pre-clinical studies and clinical trials approval and…
Dmytro Spitsyn, General Manager of Teva Ukraine, which proudly stands as the largest international company operating in the country, documents the challenges he faced and the strategies he implemented to…
Tatyana Pechaeva, Managing Director of the Lekhim Group, one of Ukraine’s top ten domestic pharmaceutical companies, shares the main principles of her strategy which have enabled Lekhim to display high…
Alexandra Sologub, managing director of Liktravy, the leading herbal pharmaceutical company in Ukraine, describes the skills she has brought over from her experience working for Darnitsa and TEVA and goes…
Victoria Tarabanova, country manager of the Ukrainian office of Wörwag Pharma, a company dedicated to treating diabetic comorbidities such as neuropathic, cardiovascular and neurological diseases, provides insights into the company’s…
See our Cookie Privacy Policy Here
